Roivant Sciences Ltd.
ROIV
Kedudukan dalam Saham
#979
Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company... Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company dedicated to discovering and advancing innovative therapeutic drugs. The firm's development pipeline targets a broad spectrum of diseases, including various forms of solid tumors and oncologic malignancies, hematological disorders like sickle cell disease and warm autoimmune hemolytic anemia, as well as rare conditions such as hypophosphatasia. Additionally, Roivant is developing treatments for immunological and dermatological ailments, including psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, thyroid eye diseases, and sarcoidosis, alongside tackling infections like staph aureus bacteremia. Founded in 2014, its operations are based in London, United Kingdom.
Harga Saham
$33.73
Disegerakkan terakhir: 2026-07-31
Modal Pasaran
$24.37B
Perubahan (1 hari)
-2.28%
Perubahan (1 tahun)
90.15%
Negara
GB
Perdagangan Roivant Sciences Ltd. (ROIV)
Kategori
Healthcare
Nisbah P/B bagi Roivant Sciences Ltd. (ROIV)
Nisbah P/B pada October 2026 TTM: 5.73
Menurut laporan kewangan dan harga saham terkini Roivant Sciences Ltd., nisbah P/B semasa (TTM) ialah 5.73. Pada akhir 2024, nisbah P/B syarikat ialah 1.37.
Sejarah nisbah P/B untuk Roivant Sciences Ltd. dari 2020 hingga 2026
Nisbah P/B pada akhir setiap tahun
| Tahun | Nisbah P/B | Ubah |
|---|---|---|
| 2026 (TTM) | 5.73 | 267.12% |
| 2025 | 1.56 | 14.08% |
| 2024 | 1.37 | -69.88% |
| 2023 | 4.54 | 127.54% |
| 2022 | 2.00 | -46.40% |
| 2021 | 3.73 | 6.30% |
| 2020 | 3.50 | 0.00% |
Nisbah P/B untuk syarikat atau pesaing yang serupa
| Syarikat | Nisbah P/B | Perbezaan Nisbah P/B | Negara |
|---|---|---|---|
| 6.251 | 9.15% |
US
|
|
| 13.2547 | 131.44% |
US
|
|
| 4.208 | -26.52% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | 7.95% |
NL
|
